Grand Pharmaceutical Group Limited (HK:0512) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Grand Pharmaceutical Group Limited has announced the approval of its first adjustable intracranial stent retriever, Luci, by China’s National Medical Products Administration. This innovative device, co-developed with Nanjing Kainite Medical Technology, offers enhanced treatment for acute ischemic stroke by allowing precise adjustment to match blood vessel diameters, promising improved safety and effectiveness. As the company expands its product pipeline, this advancement underscores its commitment to becoming a leader in cerebro-cardiovascular precision interventional therapies.
For further insights into HK:0512 stock, check out TipRanks’ Stock Analysis page.